THE INCIDENCE OF COUGH: A COMPARISON OF LISINOPRIL, PLACEBO AND TELMISARTAN, A NOVEL ANGIOTENSIN II ANTAGONIST
1999; Wiley; Volume: 53; Issue: 2 Linguagem: Inglês
10.1111/j.1742-1241.1999.tb11677.x
ISSN1742-1241
Autores Tópico(s)Heart Failure Treatment and Management
ResumoSUMMARY Dry cough is a troublesome side‐effect associated with certain antihypertensive agents that act by modulating aspects of the renin‐angiotensin‐aldosterone system. The incidence of dry cough associated with two of these therapies, the novel All receptor antagonist telmisartan and the ACE inhibitor lisinopril, was assessed in a multicentre, randomised, parallel‐group, double‐blind, placebo‐controlled, 8‐week study of 88 patients with mild to moderate hypertension who previously demonstrated ACE inhibitor‐related cough. Patients received either telmisartan 80 mg, lisinopril 20 mg, or placebo once daily. Cough incidence, measured at each visit by a self‐administered symptom assessment questionnaire, was significantly higher with lisinopril (60%) than with telmisartan (15.6%) or placebo (9.7%). A visual analogue scale demonstrated a similar trend for cough frequency. Thus the incidence of cough with telmisartan 80 mg is significantly less than that seen with lisinopril 20 mg and is comparable to placebo.
Referência(s)